Literature DB >> 28878850

Difference in F-18 FDG Uptake After Esophagogastroduodenoscopy and Colonoscopy in Healthy Sedated Subjects.

Jong-Ryool Oh1, Ji-Hyoung Seo2, Woo-Jin Chang3, Seung-Il Bae3, In-Wook Song3, Jin-Gu Bong4, Hye-Yeon Jeong4, So-Young Park5, Jeongyup Bae6, Hyundae Yoon3.   

Abstract

PURPOSE: We aimed to evaluate the difference in fluorodeoxyglucose (FDG) uptake in sedated healthy subjects after they underwent esophagogastroduodenoscopy (EGD) and colonoscopy procedures.
METHODS: The endoscopy group (n = 29) included healthy subjects who underwent screening via F-18 FDG positron emission tomography/computed tomography (PET/CT) after an EGD and/or colonoscopy under sedation on the same day. The control group (n = 35) included healthy subjects who underwent screening via PET/CT only. FDG uptake in the tongue, uvula, epiglottis, vocal cords, esophagus, stomach, duodenum, liver, cecum, colon, anus, and muscle were compared between the two groups.
RESULTS: Maximum standardized uptake value (SUVmax) in the tongue, pharynx, larynx, and esophagus did not significantly differ between the endoscopy and control groups. In contrast, mean SUVmax in the whole stomach was 18 % higher in the endoscopy group than in the control group (SUVmax: 2.96 vs. 2.51, P = 0.010). In the lower gastrointestinal track, SUVmax from the cecum to the rectum was not significantly different between the two groups, whereas SUVmax in the anus was 20 % higher in the endoscopy group than in the control group (SUVmax: 4.21 vs. 3.50, P = 0.002). SUVmax in the liver and muscle was not significantly different between the two groups. Mean volume of the stomach and mean cross section of the colon was significantly higher in the endoscopy group than in the control group (stomach: 313.28 cm3 vs. 209.93 cm3, P < 0.001, colon: 8.82 cm2 vs. 5.98 cm2, P = 0.001).
CONCLUSIONS: EGD and colonoscopy under sedation does not lead to significant differences in SUVmax in most parts of the body. Only gastric FDG uptake in the EGD subjects and anal FDG uptake in the colonoscopy subjects was higher than uptake in those regions in the control subjects.

Entities:  

Keywords:  Colonoscopy; Endoscopy; Esophagogastroduodenoscopy; FDG PET/CT

Year:  2016        PMID: 28878850      PMCID: PMC5567618          DOI: 10.1007/s13139-016-0460-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  11 in total

1.  An analysis of the physiological FDG uptake pattern in the stomach.

Authors:  Hirofumi Koga; Masayuki Sasaki; Yasuo Kuwabara; Kiyohisa Hiraka; Makoto Nakagawa; Koichiro Abe; Koichiro Kaneko; Kazutaka Hayashi; Hiroshi Honda
Journal:  Ann Nucl Med       Date:  2003-12       Impact factor: 2.668

2.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

3.  Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues.

Authors:  Yingbing Wang; Edison Chiu; Jarrett Rosenberg; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

4.  Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin.

Authors:  Jong-Ryool Oh; Ho-Chun Song; Ari Chong; Jung-Min Ha; Shin-Young Jeong; Jung-Joon Min; Hee-Seung Bom
Journal:  AJR Am J Roentgenol       Date:  2010-12       Impact factor: 3.959

5.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

6.  Incremental diagnostic utility of gastric distension FDG PET/CT.

Authors:  Pierre-Yves Le Roux; Cuong P Duong; Carlos S Cabalag; Bimal K Parameswaran; Jason Callahan; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-21       Impact factor: 9.236

Review 7.  ¹⁸F-FDG PET and PET/CT patient preparation: a review of the literature.

Authors:  Devaki Shilpa Surasi; Pradeep Bhambhvani; Jon A Baldwin; Samuel E Almodovar; Janis P O'Malley
Journal:  J Nucl Med Technol       Date:  2014-02-06

8.  The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.

Authors:  Mijin Yun; Hyun Seok Choi; Eunhye Yoo; Jung Kyun Bong; Young Hoon Ryu; Jong Doo Lee
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

Review 9.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

Authors:  P D Shreve; Y Anzai; R L Wahl
Journal:  Radiographics       Date:  1999 Jan-Feb       Impact factor: 5.333

10.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.